Lilly's dulaglutide claims the edge over Victoza in AWARD 6
This article was originally published in Scrip
Executive Summary
Eli Lilly's investigational antidiabetic dulaglutide looks set to make its presence felt in the GLP-1 agonist space on the basis of Phase III head-to-head data showing a strong performance against current market leader, Novo Nordisk's Victoza (liraglutide).